The Sustained Release Excipients Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Sustained Release Excipients Market:
https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report
According to The Business Research Company’s Sustained Release Excipients Global Market Report 2024, The sustained release excipients market size has grown strongly in recent years. It will grow from $1.29 billion in 2023 to $1.41 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to increased demand for controlled drug release, chronic disease prevalence, patient compliance and convenience, pharmaceutical industry innovations, regulatory support for extended-release formulations..
The sustained release excipients market size is expected to see strong growth in the next few years. It will grow to $1.96 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to increasing geriatric population, focus on personalized medicine, challenges in patient adherence, rise in complex drug formulations, advancements in disease management, global healthcare expansion.. Major trends in the forecast period include patient-centric drug delivery, collaborations for formulation development, regulatory compliance and safety, global expansion of drug formulation technologies, influence of biopharmaceuticals..
The increasing prevalence of chronic and acute diseases is expected to propel the growth of the sustained-release excipients market going forward. Chronic and acute diseases are two distinct categories used to classify different illnesses based on their duration and progression. Chronic diseases are long-lasting medical conditions that persist over an extended period, typically three months or more. Acute diseases are characterized by a rapid onset of symptoms that are usually severe but short-lived. These diseases develop suddenly and generally last briefly, ranging from hours to days or weeks. Sustained-release excipients are widely used to formulate pharmaceutical products for both chronic and acute diseases. It improves patient adherence, maintains consistent drug levels, reduces side effects, and improves disease management, so these factors boost the sales of sustained-release excipients. For instance, in September 2022, according to the World Health Organization (WHO), a Switzerland-based specialized health agency, cardiovascular diseases accounted for most NCD deaths, or 17.9 million people annually, followed by chronic respiratory illnesses (4.1 million), diabetes (2.0 million, including fatalities from renal disease brought on by diabetes), and cancer (9.3 million). Furthermore, in October 2022, according to an article published by the Pan American Health Organization, a US-based international public health agency, approximately 10.6 million people fell ill with tuberculosis (TB) in 2021, an increase of 4.5% from 2020. Therefore, the increasing prevalence of chronic and acute diseases drives the growth of the sustained-release excipients market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10822&type=smp
The sustained release excipients market covered in this report is segmented –
1) By Product: Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan
2) By Route of Administration: Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Other Routes of Administration
3) By Technology: Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation
Product innovation is the key trend gaining popularity in the sustained release excipients market. Major companies operating in the sustained release excipients market are developing innovative products to strengthen their position in the market. For instance, in September 2022, Nutriventia Limited, an India-based pharmaceutical company, launched Prolanza, a sustained-release ashwagandha ingredient (Withania somnifera). It is an advanced Ashwagandha root-only extract that offers continuous stress-reduction support. Prolanza’s unique release mechanism allows it to exhibit its therapeutic effects over an extended period with just one dose each day. IProlanza ashwagandha demonstrated better relative absorption, improved bioavailability, and a longer elimination half-life when compared to the control component, indicating a sustained-release profile. Prolanza’s therapeutic effects will last longer and have a higher overall good influence on health because ashwagandha is primarily used for its capacity to adapt and lessen stress responses. It’s manufactured from natural herbs and has been clinically confirmed to work.
The sustained release excipients market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
